{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:56:02Z","timestamp":1772459762002,"version":"3.50.1"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Anti-neutrophil cytoplasmic antibody (ANCA)\u2013associated vasculitis (AAV) is a systemic autoimmune disease characterized by necrotizing small-vessel inflammation, in which dysregulated adaptive immune responses play a central pathogenic role. Beyond the well-established contribution of ANCAs and innate immune activation, increasing evidence highlights profound alterations in T-cell regulation that drive persistent inflammation, autoantibody production, and organ damage. Immune checkpoints (ICs)\u2014a network of co-stimulatory and co-inhibitory pathways that fine-tune lymphocyte activation and maintain peripheral tolerance\u2014have emerged as key regulators in this process. In this review, we summarize current experimental and clinical evidence demonstrating imbalance across multiple immune checkpoint pathways in AAV, including the PD-1\/PD-L1\/PD-L2 axis, CD28\/CTLA-4, ICOS, CD40\u2013CD40L, OX40, LAG-3, TIM-3, BTLA, and CD27. We discuss how impaired inhibitory signaling combined with enhanced co-stimulatory activity promotes sustained T-cell activation, aberrant T\u2013B cell collaboration, and pathogenic ANCA production, contributing to vascular and renal injury. Importantly, both membrane-bound and soluble checkpoint molecules show disease-specific alterations in blood, urine, and renal tissue, correlating with disease activity, renal involvement, treatment response, and relapse risk. These findings position immune checkpoint components as promising biomarkers that may complement conventional clinical and serological markers. Finally, we review the current therapeutic landscape of checkpoint modulation in AAV, including clinical experience with abatacept and emerging evidence supporting PD-1 agonism and other pathway-targeted strategies derived from related autoimmune diseases. Collectively, this work highlights immune checkpoint dysregulation as a central feature of AAV pathophysiology and underscores its potential for advancing precision biomarkers and immune-targeted therapies.<\/jats:p>","DOI":"10.3389\/fmed.2026.1773241","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:00:26Z","timestamp":1772456426000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune checkpoint imbalance in ANCA-associated vasculitis: insights into disease activity and precision immunotherapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Lydia","family":"Garc\u00eda-Serrano","sequence":"first","affiliation":[{"name":"Immunology Department, Hospital Universitari de Bellvitge","place":["L\u2019Hospitalet de Llobregat, Spain"]},{"name":"Bellvitge Biomedical Research Institute (IDIBELL)","place":["L'Hospitalet de Llobregat, Spain"]},{"name":"Facultat de Medicina i ci\u00e8ncies de la salut, Universitat de Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Martinez-Valenzuela","sequence":"additional","affiliation":[{"name":"Bellvitge Biomedical Research Institute (IDIBELL)","place":["L'Hospitalet de Llobregat, Spain"]},{"name":"Nephrology Department, Hospital Universitari de Bellvitge","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Draibe","sequence":"additional","affiliation":[{"name":"Bellvitge Biomedical Research Institute (IDIBELL)","place":["L'Hospitalet de Llobregat, Spain"]},{"name":"Nephrology Department, Hospital Universitari de Bellvitge","place":["L\u2019Hospitalet de Llobregat, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/jcm10071446","article-title":"ANCA-associated vasculitis: an update","volume":"10","author":"Almaani","year":"2021","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.berh.2009.03.001","article-title":"The diagnosis of vasculitis","volume":"23","author":"Jayne","year":"2009","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.3390\/ijms26136065","article-title":"Immunopathology of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"26","author":"Lisowska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"101845","DOI":"10.1016\/j.berh.2023.101845","article-title":"Classification and epidemiology of vasculitis: emerging concepts","volume":"37","author":"Ecclestone","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.3390\/jcm11092573","article-title":"Systematic review and metaanalysis of worldwide incidence and prevalence of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis","volume":"11","author":"Redondo-rodriguez","year":"2022","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/PAP.0000000000000154","article-title":"Pathophysiology of ANCA-associated vasculitis","volume":"24","author":"Al-Hussain","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100094","DOI":"10.1016\/j.jtauto.2021.100094","article-title":"Pathogenesis and pathology of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"4","author":"Tsukui","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1261151","DOI":"10.3389\/fimmu.2023.1261151","article-title":"The involvement of NETs in ANCA-associated vasculitis","volume":"14","author":"Shiratori-Aso","year":"2023","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"6984563","DOI":"10.1155\/2018\/6984563","article-title":"Phenotypic characterization of circulating CD4+ T cells in ANCA-associated vasculitis","volume":"2018","author":"Lilliebladh","year":"2018","journal-title":"J Immunol Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature14468","article-title":"T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection","volume":"523","author":"McKinney","year":"2015","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1681\/ASN.2006020108","article-title":"Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis","volume":"17","author":"Ruth","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2023.1156212","article-title":"Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future","volume":"14","author":"Pan","year":"2023","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cellimm.2016.09.009","article-title":"PD-1\/PD-L and autoimmunity: a growing relationship","volume":"310","author":"Zamani","year":"2016","journal-title":"Cell Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"7726","DOI":"10.3390\/ijms25147726","article-title":"Exploring the role of PD-1 in the autoimmune response: insights into its implication in systemic lupus erythematosus","volume":"25","author":"Sagrero-Fabela","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fimmu.2021.673912","article-title":"CMTM6-deficient monocytes in ANCA-associated vasculitis fail to present the immune checkpoint PD-L1","volume":"12","author":"Zeisbrich","year":"2021","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/cei\/uxac002","article-title":"Increased circulating PD-1 hi CXCR5 - peripheral T helper cells are associated with disease activity of ANCA-associated vasculitis","volume":"207","author":"Liu","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s10238-022-00908-y","article-title":"Diminished PD-L1 regulation along with dysregulated T lymphocyte subsets and chemokine in ANCA-associated vasculitis","volume":"23","author":"Singh","year":"2023","journal-title":"Clin Exp Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-58550-7","article-title":"Neutrophil single-cell analysis identifies a type II interferon-related subset for predicting relapse of autoimmune small vessel vasculitis","volume":"16","author":"Nishide","year":"2025","journal-title":"Nat Commun"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clim.2008.03.506","article-title":"Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis","volume":"128","author":"Slot","year":"2008","journal-title":"Clin Immunol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.3892\/mmr.2017.8204","article-title":"Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis","volume":"17","author":"Luo","year":"2018","journal-title":"Mol Med Rep"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s12026-016-8880-0","article-title":"The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sj\u00f6gren\u2019s syndrome and systemic sclerosis","volume":"65","author":"Leg\u00e1ny","year":"2017","journal-title":"Immunol Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/j.1464-5491.2006.01951.x","article-title":"Phenotypic and genetic analyses of T-cell-mediated immunoregulation in patients with type 1 diabetes","volume":"23","author":"Tsutsumi","year":"2006","journal-title":"Diabet Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1073\/pnas.0710951105","article-title":"PD-1 deficiency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice","volume":"105","author":"Yoshida","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal vasculitis and Pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-981-32-9717-3_2","article-title":"The CD28-B7 family of co-signaling molecules","volume":"1189","author":"Nagai","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"21319","DOI":"10.1038\/s41598-022-25466-x","article-title":"Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"12","author":"Pyo","year":"2022","journal-title":"Sci Rep"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.160.7.3602","article-title":"Active Wegener\u2019s granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10","volume":"160","author":"L\u00fadv\u00edksson","year":"1998","journal-title":"J Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2019.01.049","article-title":"CD28 signaling controls metabolic fitness of pathogenic T cells in medium and large vessel vasculitis","volume":"73","author":"Zhang","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13075-021-02636-2","article-title":"Using the co-expression network of T cell-activation-related genes to assess the disease activity in Takayasu\u2019s arteritis patients","volume":"23","author":"Tian","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.12688\/f1000research.140890.1","article-title":"Association of the CD28 markers with the disease activity in systemic lupus erythematosus patients","volume":"12","author":"Pratama","year":"2023","journal-title":"F1000Res"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and cellular functions of CTLA-4","volume":"1248","author":"Van Coillie","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1046\/j.1365-2249.2001.01575.x","article-title":"Increased expression of Ctla-4 (Cd152) by T and B lymphocytes in Wegener\u2019S granulomatosis","volume":"126","author":"Steiner","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/imr.12771","article-title":"Inducible T-cell co-stimulator: signaling mechanisms in T follicular helper cells and beyond","volume":"291","author":"Panneton","year":"2019","journal-title":"Immunol Rev"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02559-4","article-title":"ICOSL: more than a trigger of ICOS function","volume":"23","author":"Stoppa","year":"2025","journal-title":"Cell Commun Signal"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1089\/jir.2022.0014","article-title":"Elevated level of serum Interleukin-21 and its influence on disease activity in anti-neutrophil cytoplasmic antibodies against myeloperoxidase-associated vasculitis","volume":"42","author":"Xu","year":"2022","journal-title":"J Interf Cytokine Res"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fimmu.2022.1015831","article-title":"Inducible costimulator ligand (ICOSL) on CD19+ B cells is involved in immunopathological damage of rheumatoid arthritis (RA)","volume":"13","author":"Ding","year":"2022","journal-title":"Front Immunol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/art.38207","article-title":"B cell-specific expression of inducible costimulator ligand is necessary for the induction of arthritis in mice","volume":"66","author":"Hamel","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00296-011-1922-y","article-title":"Expression of inducible co-stimulator on peripheral blood T lymphocytes in patients with lupus nephritis","volume":"32","author":"Li","year":"2012","journal-title":"Rheumatol Int"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"R62","DOI":"10.1186\/ar1928","article-title":"Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-gamma and anti-double-stranded DNA antibody production","volume":"8","author":"Kawamoto","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and autoimmunity: the dark side of a great activator","volume":"21","author":"Peters","year":"2009","journal-title":"Semin Immunol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00296-019-04364-y","article-title":"Cytokine profiling in anti neutrophil cytoplasmic antibody-associated vasculitis: a cross-sectional cohort study","volume":"39","author":"Hoffmann","year":"2019","journal-title":"Rheumatol Int"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.1016\/S2665-9913(20)30038-2","article-title":"Rationale for CD40 pathway blockade in autoimmune rheumatic disorders","volume":"2","author":"Pucino","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jaut.2006.02.002","article-title":"Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases","volume":"26","author":"Goules","year":"2006","journal-title":"J Autoimmun"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4049\/jimmunol.168.1.9","article-title":"Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease","volume":"168","author":"Higuchi","year":"2002","journal-title":"J Immunol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"8(DEC)","DOI":"10.3389\/fimmu.2017.01791","article-title":"The CD40-CD40L dyad in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"8","author":"Aarts","year":"2017","journal-title":"Front Immunol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12016-015-8498-3","article-title":"OX40, OX40L and autoimmunity: a comprehensive review","volume":"50","author":"Webb","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2796.2006.01688.x","article-title":"Characterization of the expanded T-cell populations in patients with Wegener\u2019s granulomatosis","volume":"260","author":"Giscombe","year":"2006","journal-title":"J Intern Med"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/ndt\/gfn461","article-title":"CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener\u2019s granulomatosis","volume":"24","author":"Wilde","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1073\/pnas.1321071111","article-title":"OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis","volume":"111","author":"Findlay","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/s13075-014-0474-4","article-title":"Soluble OX40L is associated with presence of autoantibodies in early rheumatoid arthritis","volume":"16","author":"Laustsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13075-017-1261-9","article-title":"OX40 signaling is involved in the autoactivation of CD4+CD28- T cells and contributes to the pathogenesis of autoimmune arthritis","volume":"19","author":"Jiang","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1136\/annrheumdis-2017-211499","article-title":"B cell OX40L supports T follicular helper cell development and contributes to SLE pathogenesis","volume":"76","author":"Cortini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.immuni.2015.05.012","article-title":"OX40 ligand contributes to human lupus pathogenesis by promoting T follicular helper response","volume":"42","author":"Jacquemin","year":"2015","journal-title":"Immunity"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"13","DOI":"10.55563\/clinexprheumatol\/6y0bjb","article-title":"TIM-3 regulates the NETs-mediated dendritic cell activation in myeloperoxidase-ANCA-associated vasculitis","volume":"39","author":"Su","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1189\/jlb.0910528","article-title":"Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling","volume":"89","author":"Shui","year":"2011","journal-title":"J Leukoc Biol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"104532","DOI":"10.1016\/j.cellimm.2022.104532","article-title":"The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases","volume":"376","author":"Wojciechowicz","year":"2022","journal-title":"Cell Immunol"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fimmu.2019.02843","article-title":"The co-inhibitor BTLA is functional in ANCA-associated vasculitis and suppresses Th17 cells","volume":"10","author":"Werner","year":"2019","journal-title":"Front Immunol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1681\/ASN.0000000779","article-title":"Identification of renal transcripts associated with kidney function and prognosis in ANCA-associated vasculitis","volume":"37","author":"Brilland","year":"2026","journal-title":"J Am Soc Nephrol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/cei\/uxac114","article-title":"CD27 on human memory B cells-more than just a surface marker","volume":"213","author":"Grimsholm","year":"2023","journal-title":"Clin Exp Immunol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13075-022-02796-9","article-title":"Increased frequency of IgD-CD27hiCD38hi B cells and its association with the renal involvement in ANCA-associated vasculitis","volume":"24","author":"Wang","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/ijms24032975","article-title":"Association between loss of immune checkpoint programmed cell death protein 1 and active ANCA-associated renal vasculitis","volume":"24","author":"Hakroush","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"e004660","DOI":"10.1136\/rmdopen-2024-004660","article-title":"Immune checkpoint molecules performance in ANCA vasculitis","volume":"10","author":"Anton-Pampols","year":"2024","journal-title":"RMD Open"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/art.40897","article-title":"Enhanced programmed death 1 and diminished programmed death ligand 1 up-regulation capacity of post-activated lupus B cells","volume":"71","author":"Stefanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"e12884","DOI":"10.1111\/sji.12884","article-title":"Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: association with activity and severity","volume":"92","author":"Du","year":"2020","journal-title":"Scand J Immunol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.imlet.2020.09.001","article-title":"Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity","volume":"227","author":"Tong","year":"2020","journal-title":"Immunol Lett"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard-2022-222479","article-title":"Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission","volume":"82","author":"Gamerith","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13075-020-02215-x","article-title":"Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation","volume":"22","author":"Miyazaki","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10875-013-9898-x","article-title":"Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis","volume":"33","author":"Tsurikisawa","year":"2013","journal-title":"J Clin Immunol"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener\u2019s)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, nonsevere granulomatosis with polyangiitis\n          \n          1739\n          1748\n          \n            \n              Langford\n              CA\n            \n            \n              Khalidi\n              N\n            \n            \n              Springer\n              J\n            \n            \n              Friedman\n              M\n            \n            \n              Hellmich\n              B\n            \n            \n              Pagnoux\n              C\n            \n          \n          10.1002\/art.43272\n          Arthritis Rheumatol\n          77\n          2025","DOI":"10.1002\/art.43272"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fimmu.2023.1243556","article-title":"Inhibition of T-cell activity in alopecia areata: recent developments and new directions","volume":"14","author":"Passeron","year":"2023","journal-title":"Front Immunol"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1759720X251385857","DOI":"10.1177\/1759720X251385857","article-title":"Safety, tolerability, and efficacy of the PD-1 agonist antibody JNJ-67484703 in adults with active rheumatoid arthritis: results of a multicenter, double-blind, placebo-controlled, randomized, multiple-dose phase Ib study","volume":"17","author":"Ling","year":"2025","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/jdv.14313","article-title":"Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis","volume":"31","author":"Papp","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/cpdd.918","article-title":"A phase 1 study of KHK4083: a single-blind, randomized, placebo-controlled single-ascending-dose study in healthy adults and an open-label multiple-dose study in patients with ulcerative colitis","volume":"10","author":"Furihata","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","article-title":"GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis","volume":"144","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"eaan3085","DOI":"10.1126\/scitranslmed.aan3085","article-title":"Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant","volume":"9","author":"Tkachev","year":"2017","journal-title":"Sci Transl Med"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1126\/scitranslmed.aan3085","article-title":"Brief report: a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis","volume":"70","author":"Cheng","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000146","article-title":"Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus","volume":"3","author":"Sullivan","year":"2016","journal-title":"Lupus Sci Med"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"e000146","DOI":"10.1016\/j.jaut.2023.103133","article-title":"Targeting NF-\u03baB signaling in B cells as a potential new treatment modality for ANCA-associated vasculitis","volume":"3","author":"Merino-Vico","year":"2024","journal-title":"J Autoimmun"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"103133","DOI":"10.1136\/annrheumdis-2018-214729","article-title":"Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"142","author":"Visvanathan","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/annrheumdis-2018-214729","article-title":"A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1773241\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:00:30Z","timestamp":1772456430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1773241\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":89,"alternative-id":["10.3389\/fmed.2026.1773241"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1773241","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1773241"}}